HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boots partners with P&G in Italy

This article was originally published in The Rose Sheet

Executive Summary

As part of its European expansion initiative, U.K.-based beauty and pharmacy group Alliance Boots has partnered with Procter & Gamble in Italy. Boots will "leverage P&G's sales force capacity to distribute and promote" its Boots Laboratories skin-care range to pharmacies in the country, firm says. The line - boasting "clinically proven anti-aging benefits" - launched in France and Portugal in the last two years. Boots plans to launch the range in Italy and Spain in the coming months. "Our objective is to expand Boots Laboratories, and we are delighted to be working in partnership with P&G to make these award-winning products accessible to Italian consumers," Ornella Barra, chief executive of Boots' pharmaceutical wholesale division, says in a release

You may also be interested in...



Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel